The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 10, 2017
Filed:
Feb. 25, 2014
Applicant:
Imetabolic Biopharma, Llc, Chandler, AZ (US);
Inventors:
Urban A. Kiernan, Chandler, AZ (US);
David A. Phillips, Peoria, AZ (US);
Eric E. Niederkofler, Phoenix, AZ (US);
Assignee:
iMBP Holding, LLC, Chandler, AZ (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); G01N 33/92 (2006.01); A61K 45/06 (2006.01); C12N 9/18 (2006.01); C12Q 1/44 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C12N 9/18 (2013.01); C12Q 1/44 (2013.01); G01N 33/92 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12Q 2521/537 (2013.01); G01N 2500/00 (2013.01);
Abstract
Provided herein are methods of increasing lipoprotein lipase (LPL) activity, by inhibiting apolipoprotein C3 (ApoCIII), which removes the ApoCIII inhibition of LPL, and permits VLDL to be converted to LDL. Also provided are methods for treating or preventing a lipid metabolism disorder, such as type 2 diabetes by use of an ApoCIII antagonist. Also provided are screening methods to identify ApoCIII antagonists.